Vera Therapeutics (VERA) Stock Statistics & Valuation Metrics

Vera Therapeutics has a market cap or net worth of $2.21B. The enterprise value is $2.66B.

Market Cap

$2.21B

Enterprise Value

$2.66B

Vera Therapeutics has 72,063,330 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

72,063,330

Owned by Insiders

8.78%

Owned by Institutions

36.88%

Vera Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -46.27%.

Return on Equity (ROE)

-0.50

Return on Assets (ROA)

-0.41

Return on Invested Capital (ROIC)

-46.27%

Return on Capital Employed (ROCE)

-0.46

Revenue Per Employee

0

Profits Per Employee

-829.96K

Employee Count

361

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Vera Therapeutics is -5.46. Vera Therapeutics’s PEG ratio is 0.13.

PE Ratio

-5.46

PS Ratio

0.00

PB Ratio

5.63

Price to FCF

-6.79

Price to Operating Cash Flow

-6.78

PEG Ratio

0.13

In the last 12 months, Vera Therapeutics had revenue of 0 and earned -299.62M in profits. Earnings per share was -4.66.

Revenue

0

Gross Profit

0

Operating Income

-315.47M

Pretax Income

-299.61M

Net Income

-299.62M

EBITDA

-291.62M

Earnings Per Share (EPS)

-4.66

In the last 12 months, operating cash flow was -338.65M and capital expenditures -408,000, giving a free cash flow of -339.06M billion.

Operating Cash Flow

-338.65M

Free Cash Flow

-339.06M

Free Cash Flow per Share

-4.72

Vera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-14.75%

Earnings Yield

-17.54%

Beta

1.25

52-Week Price Change

31.29%

50-Day Moving Average

32.00

200-Day Moving Average

36.75

Relative Strength Index (RSI)

56.43

Average Volume (3m)

2.06M

Vera Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 05, 2026

Next Earnings Date

Mar 25, 2027

Ex-Dividend Date

―

Vera Therapeutics as a current ratio of 13.64, with Debt / Equity ratio of 12.79%

Current Ratio

13.64

Quick Ratio

13.64

Debt to Market Cap

0.02

Net Debt to EBITDA

0.95

Interest Coverage Ratio

-41.89

In the past 12 months, Vera Therapeutics has paid 1,000 in taxes.

Income Tax

1,000

Effective Tax Rate

-0.00

Vera Therapeutics EV to EBITDA ratio is -5.90, with an EV/FCF ratio of -6.86.

EV to Sales

0.00

EV to EBITDA

-5.90

EV to Free Cash Flow

-6.86

EV to Operating Cash Flow

-6.86

Vera Therapeutics has $499.16M in cash and marketable securities with $75.23M in debt, giving a net cash position of $423.93M billion.

Cash & Marketable Securities

$499.16M

Total Debt

$75.23M

Net Cash

$423.93M

Net Cash Per Share

$5.88

Tangible Book Value Per Share

$5.68

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Vera Therapeutics is $70.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$70.09

Price Target Upside

119.24% Upside

Analyst Consensus

Strong Buy

Analyst Count

13

Revenue Growth Forecast

―

EPS Growth Forecast

-63.94%

Smart Score

7

AI Score

53